Nondaily Use of HIV Preexposure Prophylaxis in a Large Online Survey of Primarily Men Who Have Sex With Men in the United States

Whitney C Sewell, Victoria E Powell, Kenneth H Mayer, Aileen Ochoa, Douglas S Krakower, Julia L Marcus, Whitney C Sewell, Victoria E Powell, Kenneth H Mayer, Aileen Ochoa, Douglas S Krakower, Julia L Marcus

Abstract

Background: Event-driven dosing of HIV preexposure prophylaxis (PrEP) using a 2-1-1 regimen is efficacious for men who have sex with men (MSM). However, data are limited on the prevalence, correlates, and patterns of nondaily PrEP use in the United States.

Setting: Nationwide online survey.

Methods: We distributed a survey to assess experiences with PrEP, including nondaily use, in May 2019 on geosocial networking sites commonly used by MSM.

Results: Among 9697 respondents, the mean age was 43 years, 67% were non-Hispanic white, and 90% were MSM. Nearly all (91.0%) had heard of PrEP, 40.1% ever used PrEP, and 33.3% used PrEP in the past 6 months. Most (60.6%) were interested in nondaily PrEP. Those without health insurance and those with higher incomes were more likely to be interested in nondaily PrEP. Of the 3232 who used PrEP in the past 6 months, 176 (5.4%) reported nondaily use. Fewer sexual partners, frequent sex planning, and substance use were associated with nondaily use. Common reasons for nondaily use were inconsistent sexual activity (59%) and cost (49%). The most prevalent regimen was event driven (48.3%); of those, 64.7% used 2-1-1. Of nondaily users, 24.0% used PrEP on a regular schedule but not every day, including only on weekends or days starting with T or S.

Conclusions: Given substantial interest in nondaily PrEP, and use of nondaily strategies that have not been evaluated in clinical studies, there is a need for US public health authorities to provide guidance on safe and effective nondaily dosing for MSM.

References

    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men for the iPrEx Study Team* A bs t r ac t. N Engl J Med. 2010. doi:10.1056/NEJMoa1011205
    1. Anderson PL, Glidden DV., Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151). doi:10.1126/scitranslmed.3004006
    1. Marcus JL, Hurley LB, Nguyen DP, Silverberg MJ, Volk JE. Redefining HIV Preexposure Prophylaxis Failures. Clin Infect Dis. 2017;65(10):1768–1769. doi:10.1093/cid/cix593
    1. Hare CB, Coll J, Ruane P, Molina J-M, Mayer KH, Jessen H. The Phase 3 DISCOVER Study: Daily F/TAF or F/TDF for HIV pre-exposure prophylaxis In: Annual Conference on Retroviruses and Opportunistic Infections (CROI). Seattle Seattle; 2019. .
    1. Hoornenborg E, Krakower DS, Prins M, Mayer KH. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. AIDS. 2017;31(16):2179–2191. doi:10.1097/QAD.0000000000001627
    1. Marcus JL, Hurley LB, Dentoni-Lasofsky D, et al. Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California. AIDS Care - Psychol Socio-Medical Asp AIDS/HIV. 2019;31(5):536–544. doi:10.1080/09540121.2018.1533238
    1. Walensky RP, Paltiel AD. PrEP School: A Field Manual For The Battle Over HIV Prevention Drug Pricing. Health Affairs Blog. . Published August 29, 2019.
    1. Molina J-M, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373(23):2237–2246. doi:10.1056/nejmoa1506273
    1. Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–e410. doi:10.1016/S2352-3018(17)30089-9
    1. Antoni G, Tremblay C, Delaugerre C, et al. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV. November 2019. doi:10.1016/S2352-3018(19)30341-8
    1. Mitchell KM, DImitrov D, Hughes JP, et al. In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? AIDS. 2018;32(6):809–818. doi:10.1097/QAD.0000000000001766
    1. Geneva: World Health Organization. What’s the 2 + 1 + 1? Event-Driven Oral Pre-Exposure Prophylaxis To Prevent Hiv for Men Who Have Sex With Men: Update To Who’s Recommendation on Oral PrEP; 2019. .
    1. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA - J Am Med Assoc. 2018;320(4):379–396. doi:10.1001/jama.2018.8431
    1. San Francisco Department of Public Health Population Health Division Important HIV Prevention and Treatment Updates for San Francisco Providers. San Francisco, CA; 2019. .
    1. Barbot O. An “On-Demand” Dosing Schedule for PrEP to Prevent HIV. New York, NY; 2019. .
    1. New York City Health Department. “On-Demand” Dosing for PrEP: Guidance for Medical Providers. New York, NY; 2019. .
    1. CDC Centers for Disease Control and Prevention: US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2017 Update: A Clinical Practice Guideline.; 2018. .
    1. Anderson PL, García-Lerma JG, Heneine W. Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS. 2016;11(1):94–101. doi:10.1097/COH.0000000000000213
    1. Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014;210(8):1217–1227. doi:10.1093/infdis/jiu233
    1. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single-or dual-agent preexposure prophylaxis. J Infect Dis. 2015;211(8):1211–1218. doi:10.1093/infdis/jiu677
    1. Sivay MV, Li M, Piwowar-Manning E, et al. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr. 2017;75(3):271–279. doi:10.1097/QAI.0000000000001374
    1. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas. 1977. doi:10.1177/014662167700100306
    1. Hernán MA, Robins JM. Causal Inference: What If. Boca Rat Chapman Hill/CRC. 2020;2020.
    1. Marcus JL, Hurley LB, Hare CB, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr. 2016;73(5):540–546. doi:10.1097/QAI.0000000000001129
    1. Patel RR, Mena L, Nunn A, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. De Groot AS, ed. PLoS One. 2017;12(5):e0178737. doi:10.1371/journal.pone.0178737
    1. Kay ES, Pinto RM. Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue. Am J Public Health. 2019. doi:10.2105/AJPH.2019.305389
    1. Huang Y-LA, Zhu W, Smith DK, Harris N, Hoover KW. HIV Preexposure Prophylaxis, by Race and Ethnicity — United States, 2014–2016. Morb Mortal Wkly Rep. 2018;67:1147–1150. doi:10.15585/mmwr.mm6741a3
    1. Zimmermann HM, Eekman SW, Achterbergh RC, et al. Motives for choosing, switching and stopping daily or event‐driven pre‐exposure prophylaxis – a qualitative analysis. J Int AIDS Soc. 2019;22(10). doi:10.1002/jia2.25389
    1. Hoornenborg E, Achterbergh RCA, van der Loeff MFS, et al. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. J Int AIDS Soc. 2018;21(3):e25105. doi:10.1002/jia2.25105
    1. Elsesser SA, Oldenburg CE, Biello KB, et al. Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM). AIDS Behav. 2016;20(7):1400–1407. doi:10.1007/s10461-015-1238-0
    1. Hojilla JC, Satre DD, Glidden DV., et al. Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. J Acquir Immune Defic Syndr. 2019;81(1):78–82. doi:10.1097/QAI.0000000000001972
    1. Serota DP, Rosenberg ES, Sullivan PS, et al. Pre-exposure Prophylaxis Uptake and Discontinuation Among Young Black Men Who Have Sex With Men in Atlanta, Georgia: A Prospective Cohort Study. Clin Infect Dis. 2019;(Xx Xxxx):1–9. doi:10.1093/cid/ciz894
    1. Storholm ED, Volk JE, Marcus JL, Silverberg MJ, Satre DD. Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study. Prev Sci. 2017;18(6):737–747. doi:10.1007/s11121-017-0799-8
    1. Duncan DT, Park SH, Hambrick HR, et al. Characterizing Geosocial-Networking App Use Among Young Black Men Who Have Sex With Men: A Multi-City Cross-Sectional Survey in the Southern United States. JMIR mHealth uHealth. 2018;6(6):e10316. doi:10.2196/10316
    1. Zou H, Fan S. Characteristics of men who have sex with men who use smartphone geosocial networking applications and implications for HIV interventions: a systematic review and meta-analysis. Arch Sex Behav. 2017;46(4):885–894.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren